Sunday, April 26
09:45 – 11:15
Clinical trials for IPF & ILD and an overview of potential therapies moving forward
The objective of this session is to update the audience on both ongoing and coming soon clinical trials of pharmacological interventions for both idiopathic pulmonary fibrosis (IPF) and non-IPF pulmonary fibrosis. With a plain language, emphasis will be given to clinical trial methodology (i.e., primary outcomes, inclusion/exclusion criteria, sample size), mechanisms of action of the drugs under study and rationale for their potential efficacy in IPF and non-IPF pulmonary fibrosis. Finally, the session will provide an overview on compounds in earlier stages of development (i.e., phase I and phase II) as well as drugs in development for IPF-associated symptoms such as cough.
With regard to drug development and clinical trials, the session will cover the following topics:
- Connective tissue disease-associated interstitial lung disease (CTD-ILD) with emphasis on systemic sclerosis and rheumatoid arthritis and hypersensitivity pneumonitis
A sequence of presentations followed by a debate with the audience.
Please note that the programme is still updated on a regular basis until finalised.